Leather Without The Cow
Flokser launches Artificial Leather based on DuPont Tate & Lyle, BioAmber ingredients Jim Lane In Canada, BioAmber (BIOA) announced that the Flokser Group has successfully developed an innovative artificial leather fabric using bio-based materials supplied by DuPont (DD) Tate & Lyle Bio Products and BioAmber. Flokser has launched this new synthetic leather fabric under its SERTEX brand. The novel fabric comprises a polyester polyol made from BioAmber’s Bio-SA bio-based succinic acid and DuPont Tate & Lyle Bio Products’ Susterra bio-based 1,3-propanediol. Flokser’s artificial leather fabric has 70% renewable content and delivers improved performance. It provides better scratch resistance...
Novozymes Ignites Yeast Wars
Novozymes (Copenhagen:NZYM-B; OTC:NVZMY) moved into yeast this week with a new organism, Innova Drive.
It’s saccharomyces cerevisae — the workhouse yeast that has been powering wine fermentation since the days of Noah and the Ark. But here’s a new strain engineered to cut fermentation times up to two hours, and yield boosts of up to two percent.
A 2% yield increase and a 5% faster rate of production — let’s illustrate it — would mean something like 7.1 million gallons per year of more ethanol from the same standard 100 million gallon nameplate plant. Retailing at up to $10 million dollars, per year (yes,...
Amyris’ Mysterious Partner
Jim Lane In California, Amyris (AMRS) has a new partner, described fetchingly yet with near-to-complete vagueness as a “a leader in food ingredients and nutraceuticals” which is roughly as helpful as describing a person as “someone who enjoys ice cream”. Some ice cream there is, nevertheless, in this agreement, which will bring a short-term collaboration investment of $10 million, an equity investment of up to $20 million at $1.40 per share, and $100 million in annual revenue starting in 2017 connected to the production and cost improvement of fermentation molecules. One thing, and the only one, we discover...
5 Minute Guide to BioAmber
Jim Lane A quick overview of BioAmber (BIOA) Company description From the company’s 2013 S-1: “Our proprietary technology platform combines industrial biotechnology, an innovative purification process and chemical catalysis to convert renewable feedstocks into chemicals that are cost-competitive replacements for petroleum-derived chemicals. The development of our current organism was originally funded by the DOE in the late 1990s, was further developed and scaled up, and optimized at the large-scale manufacturing facility in France. “We manufacture our bio-succinic acid in a facility using a commercial scale 350,000 liter fermenter in Pomacle, France…We have produced 487,000 pounds, or 221 metric...
The Return of Advanced Biofuels
by Jim Lane
For several years now we have seen a significant number of players pivoting from biofuels towards smaller but higher-value markets in chemicals, nutrition, nutraceuticals, pharma, materials, flavorings, fragrances, cosmetics and more. We’ve reported on the proliferation of applications both in the Digest and in What’s Nuu? and indeed there’s been so much that’s Nuu, it’s been dizzying at times with all the spinning and twirling.
Capital costs and policy uncertainty have played their part, but the foot on the pedal for many has been oil prices. The scale of operations to compete with oil prices in the 2014-2017 period...
Amyris’ Missing Magic
by Debra Fiakas CFA Since the end of August last year shares of renewable chemicals developer Amyris (AMRS: Nasdaq) have been in a steady decline. Since falling through a line of price support near the $2.50 price level in early December 2014, it appears there is no safety net for AMRS. The stock set a new 52-week low in the third week in January 2015. Unfortunately, a popular technical indicator, the average directional index, is providing a very strong indication that the stock could fall even further. With its stock chart providing no hints at a reversal in...
TerraVia: No Going Back
Jim Lane At the outset of his historic Conquest, Cortés gathered the men and burned the boats. As TerraVia jettisons its break-out industrial product line and completes the pivot to Food, what lies ahead in the New World? Gromeko: They’ve shot the Czar. And all his family. Oh, that’s a savage deed. What’s it for? Zhivago: It’s to show there’s no going back. Dr. Zhivago In California, TerraVia (TVIA) recorded a loss of $27.4M for Q2 2016 on revenues of $9.9M as the company made milestone announcements in its transition from industrials to nutrition including...
Save 31% on BioAmber’s IPO
Jim Lane Will BioAmber complete its IPO? As the industry waits, fingers crossed, the biosuccinic developer sweetens the pot with warrants, lower share prices. In Canada, BioAmber has reduced the proposed price range for its IPO to $10-$12 per share, down from a $15-$17 range as it seeks to keep the initial public offering on track. Overall, the company now proposes to raise between $80 million and $110.4 million in the offering, now scheduled for May 13th according to the latest calendar from NASDAQ. At the offering’s midpoint and excluding the sale of up...
Three Renewables Companies: No Pain, No Gain
Jim Lane In California and Canada this week, BioAmber (BIOA), Pacific Ethanol (PEIX) and the former Solazyme (SZYM) reported their Q4 and year-end results, providing between them a fascinating look at the evolution in the fuels, renewable chemicals, specialty products and nutrition that make up the advanced bioeconomy. In advanced nutrition The most spectacular news of the week belonged to TerraVia (formerly SolaZyme), which landed a 5-year, $200 million “baseload” offtake deal with Unilever, which provides a huge lift for investors and validates the economics and performance of the company’s first commercial plant, which it operates in a...
Countdown To Codexis’ Day Of Reckoning
It is earnings season and bio-catalyst developer Codexis (CDXS: Nasdaq) is expected to report fourth quarter and year-end 2017 financial results in the coming weeks. The three analysts who regularly publish estimates for the company expect a nickel profit in the quarter on $23 million in total sales of the company’s custom protein catalysts. Codexis is still perfecting its proprietary platform technology called CodeEvolver, but has already delivered an array of unique enzymes that help drive critical biological processes for its customers.
Codexis does not have a good track record in terms of meeting the consensus estimate. The company has only cleared the...
From Fuel To Fudge
by Debra Fiakas CFA This week the last reminder of the renewable fuels business that was once called Solazyme will be gone. The old Solazyme has abandoned the goal of producing renewable fuels using the oils from algae. Instead, under a new name TerraVia, the company is directing its algae cultivation and harvesting knowhow toward growing edible algae for food and personal care products. To make the change complete the old stock symbol ‘SYZM’ gives way this week to a new trading symbol ‘TVIA.’ No doubt there is more than just a little hope in Terra...
Can Amyris Find The Ingredients Of Success?
In late August 2018, sustainable ingredients developer Amyris (AMRS: Nasdaq) staged a successful secondary offering by a selling stockholders, Foris Ventures and Vivo Capital Fund. In conjunction with the offering the company raised $46.0 million in new capital through the exercise of warrants held by existing shareholders. Last week the shares closed over 40% higher than the $6.25 deal price. The chief executive officer lauded shareholders for their support and apparent endorsement of the company’s game plan to commercialize sustainable alternatives to petroleum-sourced materials used in fragrance, health and beauty products.
Amyris leadership should celebrate its loyal shareholders given how far the company drifted...
Two Thumbs Up for Solazyme: AkzoNobel deal, new technology for structured oils
Jim Lane The sector’s perennial hottest company strikes again with “potentially disruptive” new technology to change the positioning and performance of triglyceride oils. In California, Solazyme (SZYM) and AkzoNobel announced an agreement targeting the development of advanced tailored triglyceride oils and commercial sales for near-term product supply. The agreement focuses on supply for the chemical giant’s Surface Chemistry and Decorative Paints businesses. Commercial supply of multi-thousand ton quantities of highly sustainable algal oil is expected to originate from the Solazyme Bunge Renewable Oils Joint Venture oil manufacturing plant in Brazil. Sales of product are anticipated to commence...
BioAmber’s $150 Million IPO: The 10-Minute Version
Jim Lane A first-to-market leader in bio-succinic acid comes to the public markets with its IPO. Can BioAmber translate a lead in succinic acid’s smallish market into leadership in a vast array of high-priced renewable chemicals? Here’s our 10-minute version of the BioAmber IPO, with a translation of the risks into English. In Minnesota, BioAmber has filed an S-1 registration statement for a proposed $150 million initial public offering. The number of shares to be offered in the proposed offering and the price range for the offering have not yet been determined. The lead book-running managers for...
Amryris: Zombie With Attitude
Jim Lane
Zombies with attitude. New partnerships for making magic molecules and exploitin’ the heck out of ’em.
These days, nothing in Hollywood beats a great zombie movie, more than 50 have been released in recent years. Zombies rise from the dead, and change everything around them. It’s not always pretty, or predictable, but they’re a disruptive force.
Well, Amyris (AMRS) is proving to be a zombie story these days starting with being labeled a “zombie company” by The Motley Fool. TMF writes:
Amyris was a pioneering industrial biotech that went from darling of the field to a company now trading well...
Gevo’s Glow
Specialty chemicals developer Gevo, Inc. (GEVO: Nasdaq) is celebrating a string of market wins for its renewable chemicals and fuels. Since its beginning thirteen years ago this month, Gevo has been doggedly perfecting its synthetic biology and chemical technologies and turning it into products that are in demand by consumers and industry. Last week shareholders were treated to an announcement by the U.S. Environmental Protection Agency (EPA) raising the amount of isobutanol for on-road use to 16% blend level from 12.5%. As a producer of renewable isobutanol Gevo will be a direct beneficiary of the EPA action. Following directly on the heels of that news,...
